Abstract:e15702 Background: Incidence of pancreatic cancer has been significantly increasing over the years and likely to become 2nd most common cause of caner death as early as 2020. One of main reasons for the high mortality rate of pancreatic cancer is the lack of sensitive and specific tools to detect in early stages. Developing an effective and credible assay platform will fill an unmet need in cancer screening and early detection. We have recently demonstrated, in two blinded independent clinical studies, the clinical utility and performance of Electric Field Induced Release and Measurement (EFIRM)-based detection of actionable EGFR mutations in plasma and saliva from non-small cell lung carcinoma (NSCLC) patients with near 100% concordance with tissue biopsy-based genotyping. We hypothesize this novel and biopsy-concordant technology is translatable to the detection/risk assessment of pancreatic ductal adenocarcinoma (PDAC). Methods: We have developed EFIRM probes for the top four KRAS mutations (G12D, G12V, G12R and G12C with > 90% frequency in total) associated with PDAC. Detection efficiency of probes for mutated KRAS was verified and optimized and subsequently tested with genomic DNA harboring a respective mutation. Results: EFIRM KRAS probes were designed and efficiency in detecting a single base KRAS mutation was optimized by utilizing synthetic oligo DNAs. Specificity and sensitivity has been further optimized by hybridization conditions, particularly by applying different electric potentials. EFIRM KRAS mutation assay efficiently differentiated a single point KRAS mutation from a wild type in sheared cellular genomic DNA harboring each of the four KRAS mutations. EFIRM is a novel detection platform ready for clinical verification to detect KRAS mutations in resectable PDAC plasma/serum samples with matched tissues. Conclusions: We have developed novel EFIRM cell free DNA KRAS assays that has a promising clinical utility as a credible, sensitive and noninvasive clinical tool in screening the patients for endoscopic evaluation and for potential prognostic/management of PDAC.

Detection of K-ras Point Mutation in Pancreatic Cancer Electrochemiluminescence-Polymerase Chain Reaction

Highly Sensitive ECL-PCR Method for Detection of K-ras Point Mutation

An ECL-PCR Method for the Detection of K-ras Point Mutation in Colorectal Cancer

Values of Mutations of K-ras Oncogene at Codon 12 in Detection of Pancreatic Cancer: 15-Year Experience

Detection Of Kras Gene Mutations In Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy For Improving Pancreatic Cancer Diagnosis

Quantitative Detection of H-ras Point Mutation in Bladder Cancer by ECL-PCR Method

A Novel Mutant Allele Specific Amplification and Electrochemiluminescence Method for the Detection of Point Mutation in Clinical Samples.

Rapid detection of K-ras oncogene point mutation by real-time fluorescence allele-specific amplification

A Method to Quantitatively Detect H-ras Point Mutation Based on Electrochemiluminescence

Rapid Detection of K-ras Gene Point Mutation in Pancreatic Adenocarcinoma by Pyrosequencing

An Ecl-Pcr Method For Quantitative Detection Of Point Mutation

K-ras Point Mutation Detection in Colorectal Cancer:Comparison of Two Approaches Using Allele Specific Amplification

Differential High-Resolution Melting Analysis for the Detection of K-ras Codons 12 and 13 Mutations in Pancreatic Cancer.

Detection Of K-Ras Gene Mutations In Feces By Magnetic Nanoprobe In Patients With Pancreatic Cancer: A Preliminary Study

Clinical Validity of Electric Field Induced Release and Measurement (efirm) for Kras Mutation Detection in Circulating Dna Associated with Pancreatic Ductal Adenocarcinoma.

The Diagnostic Value of the K-ras Mutation Detection of Endoscopic Ultrasound-Guided Fine Needle Aspiration Specimen for Pancreatic Carcinoma

Lateral flow strip for visual detection of K-ras mutations based on allele-specific PCR

Establishment of pyrosequencing method for detection of k-ras mutation

Detection of K-ras Gene Mutation at Codon 12 by Pancreatic Duct Brushing for Pancreatic Cancer.

A Novel Nanoprobe-Based Assay for Detecting K-ras Mutations in Plasma and Stool Samples from Patients with Pancreatic Cancer: Value in Diagnosis and Prognosis Evaluation

Detection of K-ras mutation in advanced colorectal carcinoma by Pyrosequencing